Newswise — NEW YORK, NEW YORK: December 21, 2020— The Frontline COVID-19 Critical Care Alliance (FLCCC) has released a one-page summary of the most up-to-date clinical trials evidence supporting the use of ivermectin in the treatment of all stages of COVID-19—from prevention to serious illness. Their comprehensive scientific review manuscript of all the referenced clinical trials can be found on the Open Science Foundation pre-print server.   

“We created the summary to provide a quick overview of the numerous controlled clinical trials from multiple centers and countries worldwide,” said Dr. Pierre Kory, lead FLCCC Alliance author of the scientific review. “These studies are reporting consistent, large magnitude improvements in COVID-19 patient outcomes when treated with ivermectin. Our comprehensive manuscript is currently in expedited peer-review by a major American medical journal and has also been submitted by request to multiple national and international health care agency committees tasked with reviewing the emerging evidence supporting ivermectin.” 

Additionally, the news being reported from England about an emerging, mutant strain of the virus has led to questions from people wanting to know if Ivermectin will continue to be effective against this new strain. “We have no concerns about the effectiveness of ivermectin in regard to a new strain,” noted Dr. Kory. “Ivermectin has been shown to be effective against many different viruses, and has multiple mechanisms of action in which it prevents both replication and entry of viruses in tissues.  Given that, in SARS-CoV-2,  ivermectin appears  to bind to the spike protein as well as interfere with multiple other proteins needed for replication and entry of the virus, our estimate is that it will remain a potent anti-viral in COVID-19, even against a new strain.  

MEDIA: For more information or to arrange for an interview, email [email protected]

SEE ORIGINAL STUDY